中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
12期
1273-1276
,共4页
代玉川%李传方%甘立军%张猛%程云涛%郭军霞
代玉川%李傳方%甘立軍%張猛%程雲濤%郭軍霞
대옥천%리전방%감립군%장맹%정운도%곽군하
原发性高血压%AT2受体基因%吲达帕胺缓释片%多态性
原髮性高血壓%AT2受體基因%吲達帕胺緩釋片%多態性
원발성고혈압%AT2수체기인%신체파알완석편%다태성
Primary hypertension%AT2R gene%Indapamide sustained release tablets%Polymorphism
目的 探讨原发性女性高血压患者的AT2受体基因1675A/G多态性与吲达帕胺缓释片降压疗效的相关性.方法 用吲达帕胺缓释片(1.5 mg1次/d),对220例原发性女性高血压患者进行为期8周的降压治疗,用聚合酶链反应( PCR)、高分辨率熔解曲线(HRM)及基因测序方法检测患者的AT2受体基因多态性.结果 205例患者完成了试验,在女性患者中基因型AA、AG和GG应用吲达帕胺缓释片有效率分别为70.6％、71.6％、71.4％,三者比较差异无统计学意义(x2=2.53,P=0.49)；收缩压及缩张压降低幅度比较差异亦无统计学意义(F值分别为0.39、0.19,P均＞0.05).结论 AT2受体基因1675A/G多态性可能对吲达帕胺缓释片在女性患者降压疗效中不存在影响.
目的 探討原髮性女性高血壓患者的AT2受體基因1675A/G多態性與吲達帕胺緩釋片降壓療效的相關性.方法 用吲達帕胺緩釋片(1.5 mg1次/d),對220例原髮性女性高血壓患者進行為期8週的降壓治療,用聚閤酶鏈反應( PCR)、高分辨率鎔解麯線(HRM)及基因測序方法檢測患者的AT2受體基因多態性.結果 205例患者完成瞭試驗,在女性患者中基因型AA、AG和GG應用吲達帕胺緩釋片有效率分彆為70.6％、71.6％、71.4％,三者比較差異無統計學意義(x2=2.53,P=0.49)；收縮壓及縮張壓降低幅度比較差異亦無統計學意義(F值分彆為0.39、0.19,P均＞0.05).結論 AT2受體基因1675A/G多態性可能對吲達帕胺緩釋片在女性患者降壓療效中不存在影響.
목적 탐토원발성녀성고혈압환자적AT2수체기인1675A/G다태성여신체파알완석편강압료효적상관성.방법 용신체파알완석편(1.5 mg1차/d),대220례원발성녀성고혈압환자진행위기8주적강압치료,용취합매련반응( PCR)、고분변솔용해곡선(HRM)급기인측서방법검측환자적AT2수체기인다태성.결과 205례환자완성료시험,재녀성환자중기인형AA、AG화GG응용신체파알완석편유효솔분별위70.6％、71.6％、71.4％,삼자비교차이무통계학의의(x2=2.53,P=0.49)；수축압급축장압강저폭도비교차이역무통계학의의(F치분별위0.39、0.19,P균＞0.05).결론 AT2수체기인1675A/G다태성가능대신체파알완석편재녀성환자강압료효중불존재영향.
Objective To investigate the relationship of the1675A/G polymorphism of AT2 gene with the therapeutic effect of indapamide sustained release tablets in female patients with primary hypertension.Methods Two hundred and twenty female patients with primary hypertension were treated with Indapamide Sustained Release Tablets ( 1.5 mg · qd) for 8 weeks.The blood samples from the patients were collect to determine AT2 gene polymorphism by PCR combined with HRM and sequencing.Results Two hundred and five patients completed the test.In female patients,the therapeutic efficacy of indapamide sustained telease tablets among different AT2R genotypes( AA:70.6％,AG:71.6％,GG:71.4％ ) showed no significant difference ( x2=2.53,P=0.49 ),neither do the decline of BP after therapy ( F=0.39 and 0.19 respecrively,P ＞ 0.05).Conclusion The AT2 genotype was assumed to be not correlated to the blood pressure lowering response to Indapamide Sustained Release Tablets in female primary hypertension patients.
